Nitroimidazole Amide Compounds for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis, particularly those involving nitroimidazole compounds like PA-824 and OPC-67683, face challenges such as long treatment cycles, serious adverse reactions, and limited effectiveness against multi-drug resistant Mycobacterium tuberculosis due to low water solubility and bioavailability.
Innovation Solution
Development of a novel nitroimidazole compound with improved water solubility and bioavailability, specifically designed for oral administration, which combines with existing first-line antituberculosis drugs to effectively target drug-resistant bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitroimidazole compounds (PA-824, OPC-67683) are used to treat tuberculosis, then antitubercular activity is achieved, but water solubility and bioavailability are low
Solution Approach 1:
The patent modifies the chemical structure of nitroimidazole compounds by introducing specific substituent groups (R1-R6) with different polarities and hydrophobicities. This structural parameter change optimizes the balance between water solubility and membrane permeability, thereby improving bioavailability while maintaining antitubercular activity
Solution Approach 2:
The invention creates composite molecular structures combining the nitroimidazole core with various functional groups (amides, esters, heterocyclic rings). These composite structures achieve synergistic effects where the core provides antitubercular activity while the attached groups enhance solubility and pharmacokinetic properties
2Ease of operation
If complex tablet formulation is used for PA-824, then oral administration becomes possible, but formulation complexity increases
Solution Approach 1:
By modifying the chemical structure to improve inherent water solubility, the patent reduces the need for complex formulation strategies. The improved solubility parameter allows for simpler tablet formulations with fewer excipients and less complex manufacturing processes
3Reliability
If current first-line drugs (rifampicin, isoniazide) are used for treatment, then antitubercular effect is achieved, but serious adverse reactions occur
Solution Approach 1:
The patent develops new nitroimidazole compounds that copy the successful mechanism of action of existing antitubercular drugs while introducing structural modifications. This allows the new compounds to maintain effectiveness against Mycobacterium tuberculosis while potentially reducing toxicity associated with conventional drugs
4Reliability
If conventional treatment combinations are used, then treatment coverage is achieved, but treatment cycle duration is long
Solution Approach 1:
The patent optimizes pharmacokinetic parameters including half-life, bioavailability, and tissue penetration of the nitroimidazole compounds. These parameter improvements enable more effective bacterial killing rates and longer duration of action, potentially shortening the overall treatment cycle while maintaining adequate treatment coverage
Data Source
Figure 1
AI summary
(6,7-Dihydro-2-nitro-5H-imidazo [2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the description. The uses of said compounds in preparing medicaments for treating infectious diseases caused by Mycobacterium tuberculosis, especially infectious diseases caused by multi-drug resistance Mycobacterium tuberculosi are also disclosed.